TY - JOUR
T1 - Evaluation of weight change and cardiometabolic risk factors in a real-world population of US adults with overweight or obesity
AU - Pagidipati, Neha J.
AU - Mulder, Hillary
AU - Chiswell, Karen
AU - Lampron, Zachary
AU - Jones, William S.
AU - Machineni, Sriram
AU - Waitman, Lemuel R.
AU - Mongraw-Chaffin, Morgana
AU - Waterman, Fanta
AU - Kumar, Neela
AU - Ramasamy, Abhilasha
AU - Smolarz, Gabriel
AU - Peterson, Eric D.
AU - O'Brien, Emily
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/5
Y1 - 2023/5
N2 - Whether individuals in real-world settings are able to lose weight and improve cardiometabolic risk factors over time is unclear. We aimed to determine the management of and degree of body weight change over 2 years among individuals with overweight or obesity, and to assess associated changes in cardiometabolic risk factors and clinical outcomes. Using data from 11 large health systems within the Patient-Centered Outcomes Research Network in the U.S., we collected the following data on adults with a recorded BMI ≥25 kg/m2 between January 1, 2016 and December 31, 2016: body-mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL[sbnd]C), triglycerides and glycated hemoglobin (HbA1c). We found that among 882,712 individuals with BMI ≥25 kg/m2 (median age 59 years; 56% female), 52% maintained stable weight over 2 years and 1.3% utilized weight loss pharmacotherapy. Weight loss of 10% was associated with small but significant lowering of mean SBP (−2.69 mmHg [95% CI -2.88, −2.50]), DBP (−1.26 mmHg [95% CI -1.35, −1.18]), LDL-C (−2.60 mg/dL [95% CI -3.14, −2.05]), and HbA1c (−0.27% [95% CI -0.35, −0.19]) in the same 12 months. However, these changes were not sustained over the following year. In this study of adults with BMI ≥25 kg/m2, the majority had stable weight over 2 years, pharmacotherapies for weight loss were under-used, and small changes in cardiometabolic risk factors with weight loss were not sustained, possibly due to failure to maintain weight loss.
AB - Whether individuals in real-world settings are able to lose weight and improve cardiometabolic risk factors over time is unclear. We aimed to determine the management of and degree of body weight change over 2 years among individuals with overweight or obesity, and to assess associated changes in cardiometabolic risk factors and clinical outcomes. Using data from 11 large health systems within the Patient-Centered Outcomes Research Network in the U.S., we collected the following data on adults with a recorded BMI ≥25 kg/m2 between January 1, 2016 and December 31, 2016: body-mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL[sbnd]C), triglycerides and glycated hemoglobin (HbA1c). We found that among 882,712 individuals with BMI ≥25 kg/m2 (median age 59 years; 56% female), 52% maintained stable weight over 2 years and 1.3% utilized weight loss pharmacotherapy. Weight loss of 10% was associated with small but significant lowering of mean SBP (−2.69 mmHg [95% CI -2.88, −2.50]), DBP (−1.26 mmHg [95% CI -1.35, −1.18]), LDL-C (−2.60 mg/dL [95% CI -3.14, −2.05]), and HbA1c (−0.27% [95% CI -0.35, −0.19]) in the same 12 months. However, these changes were not sustained over the following year. In this study of adults with BMI ≥25 kg/m2, the majority had stable weight over 2 years, pharmacotherapies for weight loss were under-used, and small changes in cardiometabolic risk factors with weight loss were not sustained, possibly due to failure to maintain weight loss.
KW - Cardiometabolic
KW - Obesity
KW - Weight change
UR - http://www.scopus.com/inward/record.url?scp=85151542771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151542771&partnerID=8YFLogxK
U2 - 10.1016/j.ypmed.2023.107496
DO - 10.1016/j.ypmed.2023.107496
M3 - Article
C2 - 36997096
AN - SCOPUS:85151542771
SN - 0091-7435
VL - 170
JO - Preventive Medicine
JF - Preventive Medicine
M1 - 107496
ER -